Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria

INTRODUCTION: To complement results of the SUSTAIN program, this study assessed effectiveness and safety of once weekly subcutaneous semaglutide in people with type 2 diabetes (T2D) managed under routine care. METHODS: This was a multicenter, observational, retrospective study including all patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Loreto, Chiara, Minarelli, Viviana, Nasini, Giovanni, Norgiolini, Roberto, Del Sindaco, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886341/
https://www.ncbi.nlm.nih.gov/pubmed/35230650
http://dx.doi.org/10.1007/s13300-022-01218-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886341/
https://www.ncbi.nlm.nih.gov/pubmed/35230650
http://dx.doi.org/10.1007/s13300-022-01218-y

Ejemplares similares